Latest in The Library » Sofie Biosciences and OsiriX announce the release of open-source translational image analysis software.
Our Vision
We believe the time for decentralized PET is now. The old world would have you think that incorporating PET into your research plans means relying on specially trained technicians or costly capital investment in equipment and site planning – we respectfully disagree. We live in the new world, the one in which the entire preclinical PET platform – from radiochemistry, to probes, to instrumentation – is readily available on your lab bench, easy to use and operate, and priced reasonably.
PET imaging enables basic and clinical researchers to visualize and characterize the biology of disease, monitor progression, and evaluate therapeutic efficacy. Continual advances in the biology, chemistry, and instrumentation surrounding preclinical PET allow users to move quickly from cell
to mouse to man, all with the same biomarkers, biological assays, and imaging approach.
By empowering a wide array of researchers with valuable, translational imaging tools, we are removing the dependency, cost, and complexity from PET. To usher in the new world of accessible molecular medicine, we are committed to new technologies developed by great people with great ideas.
We believe the time for decentralized PET is now. The old world would have you think that incorporating PET into your research plans means relying on specially trained technicians or costly capital investment in equipment and site planning – we respectfully disagree. We live in the new world, the one in which the entire preclinical PET platform – from radiochemistry, to probes, to instrumentation – is readily available on your lab bench, easy to use and operate, and priced reasonably.
PET imaging enables basic and clinical researchers to visualize and characterize the biology of disease, monitor progression, and evaluate therapeutic efficacy. Continual advances in the biology, chemistry, and instrumentation surrounding preclinical PET allow users to move quickly from cell
to mouse to man, all with the same biomarkers, biological assays, and imaging approach.
By empowering a wide array of researchers with valuable, translational imaging tools, we are removing the dependency, cost, and complexity from PET. To usher in the new world of accessible molecular medicine, we are committed to new technologies developed by great people with great ideas.